Solid Biosciences (SLDB) Other Working Capital Changes (2023 - 2026)
Solid Biosciences (SLDB) reported Other Working Capital Changes of -$496000.0 for Q1 2026, down 19.23% on a YoY basis from -$614095.2 in Q1 2025, and little changed sequentially from -$495000.0 in Q4 2025.
Solid Biosciences (SLDB) Other Working Capital Changes (2023 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 4 years of Other Working Capital Changes data on file, last reported at -$496000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Working Capital Changes fell 19.23% year-over-year to -$496000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.9 million (down 15.26% YoY), and the FY2025 full-year result was -$1.8 million, down 6.56% from the prior year.
- Other Working Capital Changes was little changed at -$496000.0 in Q1 2026, from -$495000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $7.6 million in Q4 2025 to a low of -$6.2 million in Q2 2022.
- A 5-year average of $324437.5 and a median of -$273000.0 in 2024 frame the typical range for Other Working Capital Changes.
- Across the five-year window, Other Working Capital Changes grew 12.66% in 2024 and declined 19.57% in 2025, its largest moves.
- Tracing SLDB's Other Working Capital Changes over 4 years: stood at -$474000.0 in 2023, then gained by 12.66% to -$414000.0 in 2024, then declined by 19.57% to -$495000.0 in 2025, then retreated by 0.2% to -$496000.0 in 2026.
- Business Quant data shows SLDB's Other Working Capital Changes at -$496000.0 in Q1 2026, -$495000.0 in Q4 2025, and -$443000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -496,000.00 |
| Mar 31, 2026 | -496,000.00 |
| Mar 31, 2026 | -496,000.00 |
| Dec 31, 2025 | -495,000.00 |
| Dec 31, 2025 | -495,000.00 |
| Dec 31, 2025 | -495,000.00 |
| Sep 30, 2025 | -443,000.00 |
| Sep 30, 2025 | -443,000.00 |
| Sep 30, 2025 | -443,000.00 |
| Jun 30, 2025 | -432,000.00 |
| Jun 30, 2025 | -432,000.00 |
| Jun 30, 2025 | -432,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Dec 31, 2024 | -414,000.00 |
| Dec 31, 2024 | -414,000.00 |
| Dec 31, 2024 | -414,000.00 |
| Sep 30, 2024 | -398,000.00 |
| Sep 30, 2024 | -398,000.00 |